{"schema_version":"secwatch.filing_event.v1","accession":"0001739104-25-000052","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.846489+00:00","generated_at":"2026-05-17T17:57:08.736786+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elanco Q2 rev +5% to $1.24B, raises FY2025 outlook; net leverage target improved","bullets":["Q2 revenue $1,241M (+5% reported, +8% organic CC); adjusted EPS $0.26 vs $0.30 prior year.","FY2025 revenue guidance raised to $4,570-4,620M; adjusted EPS raised to $0.85-0.91.","Full-year innovation revenue target increased by $60M to $720-800M; Credelio Quattro and Experior drive growth.","Net leverage ratio improved to 4.0x at Q2 end; year-end target tightened to 3.8x-4.1x.","Robert VanHimbergen appointed EVP and CFO effective July 7, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001739104-25-000052","json":"https://secwatch.observer/filing/0001739104-25-000052.json","markdown":"https://secwatch.observer/filing/0001739104-25-000052.md","text":"https://secwatch.observer/filing/0001739104-25-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000173910425000052/0001739104-25-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000173910425000052/elan-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:57:08.736786+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}